2026-05-27T15:08:54Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/447082026-02-03T11:23:21Zcom_10630_2254col_10630_37953

Domínguez-López, Inés Lamuela-Raventós, Rosa M. Razquin, Cristina Arancibia-Riveros, Camila Galkina, Polina Salas-Salvadó, Jordi Alonso-Gómez, Ángel M. Fitó, Montserrat Fiol, Miquel Lapetra, José Gómez-Gracia, Enrique Sorlí, José V. Ruiz-Canela, Miguel Castañer, Olga Liang, Liming Serra-Majem, Lluís Hu, Frank B. Ros, Emilio Martínez-González, Miguel Ángel Estruch, Ramón 2026-01-22T09:40:38Z 2025-01-07 Domínguez-López I, Lamuela-Raventós RM, Razquin C, Arancibia-Riveros C, Galkina P, Salas-Salvadó J, Alonso-Gómez ÁM, Fitó M, Fiol M, Lapetra J, Gómez-Gracia E, Sorlí JV, Ruiz-Canela M, Castañer O, Liang L, Serra-Majem L, Hu FB, Ros E, Martínez-González MÁ, Estruch R. Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial. Eur Heart J. 2025 Jan 7;46(2):161-172. doi: 10.1093/eurheartj/ehae804. PMID: 39689849; PMCID: PMC11704392. https://hdl.handle.net/10630/44708 10.1093/eurheartj/ehae804 Background and Aims Moderate wine consumption has been associated with lower cardiovascular disease (CVD) risk in older populations. However, wine consumption information through self-reports is prone to measurement errors inherent to subjective as- sessments. The aim of this study was to evaluate the association between urinary tartaric acid, an objective biomarker of wine consumption, and the rate of a composite clinical CVD event. Methods A case-cohort nested study was designed within the PREDIMED trial with 1232 participants: 685 incident cases of CVD and arandom subcohort of 625 participants (including 78 overlapping cases). Wine consumption was registered using validated food frequency questionnaires. Liquid chromatography-tandem mass spectrometry was used to measure urinary tartaric acid at base-line and after one year of intervention. Weighted Cox regression models were used to estimate hazard ratios (HRs) of CVD. Results Tartaric acid was correlated with self-reported wine consumption at baseline [r = 0.46 (95% CI 0.41; 0.50)]. Five categories of post hoc urinary tartaric acid excretion were used for better representation of risk patterns. Concentrations of 3–12 and 12–35 μg/mL, which reflect ∼3–12 and 12–35 glasses/month of wine, were associated with lower CVD risk [HR 0.62 (95% CI 0.38; 1.00), P = .050 and HR 0.50 (95% CI 0.27; 0.95), P = .035, respectively]. Less significant associations between self- reported wine consumption and CVD risk were observed. eng http://creativecommons.org/licenses/by/4.0/ open access Atribución 4.0 Internacional Marcadores bioquímicos Sistema cardiovascular - Enfermedades Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial journal article